Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-17

FDA Approved: KABIVEN — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for KABIVEN, a complete parenteral nutrition product, confirming its labeling and continued use for patients requiring p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KABIVEN

Snippet

SUPPL AP for KABIVEN (DEXTROSE, SOYBEAN OIL, ELECTROLYTES, LYSINE, PHENYLALANINE, LEUCINE, VALINE, THREONINE, METHIONINE, ISOLEUCINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, HISTIDINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE)